Stephen MacMillan, Hologic CEO (Photo by Riccardo Savi/Getty Images for Concordia Summit)

June 2, 2023 11:22 AM EDTUpdated 11:37 AM

Illumina names Hologic CEO as new board member and chair

Jared Whitlock

Features Editor

Illumina’s board appointed two new members, including Hologic CEO Stephen MacMillan as the non-executive chair, a move that followed a proxy fight that saw shareholders …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Illumina names Hologic CEO as new board member and chair

Jared Whitlock

Features Editor

Sign up to read this article for free.

China’s biotech market is staging a comeback that US biotech can only wish for

Large vaccine makers stand by their investments despite US headwinds

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

Genentech vet launches ADC startup with $20M

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Il­lu­mi­na names Ho­log­ic CEO as new board mem­ber and chair

Jared Whitlock

Features Editor

Sign up to read this article for free.

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

Large vac­cine mak­ers stand by their in­vest­ments de­spite US head­winds

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Genen­tech vet launch­es ADC start­up with $20M

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

Illumina names Hologic CEO as new board member and chair

China’s biotech market is staging a comeback that US biotech can only wish for

Large vaccine makers stand by their investments despite US headwinds

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

Genentech vet launches ADC startup with $20M

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence